SLU-PP-332 (ERR Pan-Agonist)

SLU-PP-332: The Mitochondrial Exercise Mimetic

Chemical Name: (E)-4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide Format: Oral Tablets Class: Estrogen-Related Receptor (ERR) Pan-Agonist Purity: ≥98% (HPLC) Target: ERRα, ERRβ, and ERRγ Transcriptional Networks

Product Overview

SLU-PP-332 is a first-in-class small molecule designed to function as an "exercise mimetic." Developed through a collaboration between Saint Louis University and Washington University, it acts as a potent pan-agonist of the Estrogen-Related Receptor (ERR) family.

Unlike standard weight-loss agents that target appetite, SLU-PP-332 operates directly on peripheral tissues. It induces a high-oxidative state in skeletal muscle, effectively "tricking" the body into simulating the systemic benefits of endurance training. It is a premier tool for researching the reversal of metabolic syndrome, obesity, and age-related physiological decline through direct transcriptional modulation.

Mechanism of Action: Transcriptional Fat Burning

SLU-PP-332 bypasses mechanical work to activate the genetic programs associated with physical exertion.

• ERR Activation: Specifically targets ERRα, the master regulator of mitochondrial biogenesis. It stabilizes the active conformation of the receptor, allowing for the recruitment of the co-activator PGC-1α.

• Mitochondrial Overdrive: Upregulates the Pdk4 gene, which switches cellular fuel preference from glucose to fatty acids. This results in a 2.5x increase in mitochondrial DNA and enhanced ATP production within myocytes.

• Tissue Remodeling: Promotes the development of Type IIa oxidative muscle fibers, which are highly resistant to fatigue.

• STING Pathway Inhibition: In aging models, it has been shown to shutdown the cGAS-STING inflammatory response, protecting vital organs like the kidneys from age-related decline.

Key Research Applications

1. Endurance & Physical Performance Investigated for its ability to dramatically enhance aerobic capacity. In animal models, subjects treated with SLU-PP-332 were able to run 70% longer and 45% further on treadmill tests compared to controls, despite no increase in actual physical activity.

2. Obesity & Metabolic Syndrome Research in Diet-Induced Obesity (DIO) models shows a 12% reduction in total body weight and a 10-fold reduction in fat accumulation. The weight loss is driven by a ~25% increase in whole-body fat oxidation and resting energy expenditure.

3. Geroprotection (Kidney & Muscle) Studies in aged mice demonstrate that SLU-PP-332 reverses podocyte loss in the kidney and reduces albuminuria. It also promotes human myotube formation and fiber diameter, offering a model for treating sarcopenia and muscle atrophy.

4. Cardiovascular Support Investigated for its ability to improve ejection fraction and survival rates in models of heart failure by normalizing oxidative phosphorylation profiles without inducing pathological hypertrophy.

Storage & Handling

• Physical State: Standardized oral tablets for precise experimental protocols.

• Storage: Store in a cool, dry place away from direct light.

• Long-Term Storage: Store at -20°C (Freezer) to maintain stability for up to 4 years.

• Stability: Highly stable in tablet form; the lyophilized powder is resistant to degradation at room temperature for up to 3 weeks during transit.

Disclaimer

FOR RESEARCH USE ONLY. This product is a chemical compound intended strictly for laboratory research and development. It is not approved by the FDA for clinical use, diagnostics, or therapeutic procedures in humans or animals. The physiological and toxicological properties of this chemical have not been fully investigated.